Exclusive Summary

• Original patents have long expired, presenting zero IP barriers and allowing fast, risk-free import and distribution by overseas partners.
• With rigidly stable niche demand in ICUs for severe COPD exacerbations and post-anesthesia recovery, the drug frequently faces global supply shortages, providing an excellent market-entry opportunity.
• Backed by highly efficient Chinese manufacturing, it offers robust cost and supply chain advantages, ensuring lucrative profit margins for distributors in hospital tenders and private markets.